Edition:
India

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

19.82EUR
2:44pm IST
Change (% chg)

€0.32 (+1.64%)
Prev Close
€19.50
Open
€19.50
Day's High
€19.90
Day's Low
€19.50
Volume
1,408
Avg. Vol
5,023
52-wk High
€28.90
52-wk Low
€18.00

Summary

Name Age Since Current Position

Jean-Pierre Garnier

71 2018 Chairman of the Board

Stephane Piat

2017 Chief Executive Officer, Director

Pascale d'Arbonneau

2018 Chief Financial Officer, Chief Administrative Officer, IR Contact Officer

Marc Grimme

Technical Director

Eric Richez

2014 Director of Business Development

Francesco Arecchi

2017 Director of Marketing

Raouia Bouyanzer

Director of Human Resources

Thierry Dupoux

2018 Senior Director of Quality Assurance

Wenzel Hurtak

Director of Manufacturing

Petrus Jansen

2009 Medical Director

Alain Carpentier

2013 Director

Anne-Pascale Guedon

2015 Director - Representative of Matra Defense

Antonino Ligresti

80 2016 Director - Representative of Sante Holdings SRL

Philippe Pouletty

59 2010 Representative of Truffle Capital on the Board of Directors

Pierre Bastid

2018 Independent Director

Henri Lachmann

80 2010 Independent Director

Jean-Luc Lemercier

61 2017 Independent Director

Michael Mack

2017 Independent Director

Biographies

Name Description

Jean-Pierre Garnier

Dr. Jean-Pierre Garnier has been appointed as Chairman of the Board at Carmat SA as of December 3, 2018. Scientist and business leader, Mr. Garnier graduated from Universite Louis Pasteur (PhD in Pharmacology) and Stanford University (Master in Business Administration). He started his career in 1975 at the pharmaceutical company Schering-Plough where he held a number of management positions in Europe before becoming President of their American division. In 1990, he joined Smithkline Beecham Laboratories as President of the Pharmaceuticals Division and became President and CEO in 1999. In 2000, he achieved the merge of two of the largest pharmaceutical groups (Smithkline Beecham and Glaxo Wellcome), to create GlaxoSmithKline (GSK), which he chaired until 2008. He is currently a member of the Board of Directors of several biotechnology companies; President of Idorsia, Director of Radius Health. He is also a member of the Board of United Technology (Aeronautics) and a Director of the Paul Newman Foundation. From 2011, Mr. Garnier was Chairman of Actelion (Biotechnology) until its acquisition by Johnson and Johnson in 2017. The Best Practice Institute has nominated Jean-Pierre Garnier as one of the world's top 20 CEOs. He is an Officier de la Legion d’Honneur (Officer of the Legion of Honour) and Knight Commander of the Order of the British Empire.

Stephane Piat

Mr. Stephane Piat has been Chief Executive Officer and Director of Carmat SA since April 27, 2017. He was appointed as Chief Executive Officer as of August 29. 2016. He is currently also Director at Triflo Cardiovascular Inc. He started his career at Becton Dickinson European Headquarters as a Market Researcher in 1995. He was appointed European Platform Leader for Locoregional Anaesthesia five years later. In 2002, he joined Cordis, a Johnson & Johnson company, where he spent five years in several management positions ranging from Business Director France to European Marketing Director for Cardiology. In 2007, he moved to Abbott Vascular as General Manager for mid-size countries, EMEA, and two yearslater oversaw the integration of Evalve as the company’s General Manager EMEA, heading clinical and commercial development of a new interventional cardiology product, Mitraclip. In 2014, he led Global Market Development of the Abbott Vascular Structural Heart Division in San Francisco as Division Vice President. Mr Piat holds a master’s degree in Management Science from IAE Dijon, and a post-graduate degree in Quantitative Marketing from ESA business school in Grenoble (now IAE Grenoble).

Pascale d'Arbonneau

Ms. Pascale d'Arbonneau has been appointed as Chief Financial and Administrative Officer of CARMAT SA as of December 12, 2018. She is a member of the National Association of Financial and Management Control (DFCG) and a lecturer at the University Paris Diderot. She is graduate of ESCP. Before joining CARMAT, Ms. d'Arbonneau was Executive Director at the Econocom International B.V. (EIBV) family office. She began her career in 1989 as an auditor at Coopers & Lybrand (now PWC) before joining the pharmaceutical industry as Finance & IT Director France at Johnson & Johnson - MSD (1995-1999). She spent most of her career (1999-2016) at GlaxoSmithKline (GSK). She started as Director of Management Control France at GlaxoWellcome, before the merger with SmithKline Beecham, where she led a team of 20 people working on the merger of the two companies. She then held several senior positions within the Group (Vice President Financial Control Pharma Europe from 2006 to 2010, Vice President and Chief Financial Officer Western Europe from 2010 to 2014) before becoming Vice President Finance in charge of the integration of Compliance and Control at worldwide level.

Marc Grimme

Mr. Marc Grimme is the Technical Director of Carmat SA. Since 1996, he has served as the GIE CARMAT program’s technical project leader and thus has more than 10 years of experience in the artificial heart field. From 1991 to 1996, he worked in all areas related to the development of mission-critical electronics at MBDA France, from upstream studies and the design phase to production commissioning for missile systems such as image processing modules, launch equipment and ordnance systems. Mr. Grimme is graduate of ISEN.

Eric Richez

Mr. Eric Richez has been Director of Business Development at Carmat SA since September 2014. He has over 13 years’ experience in sales & marketing with Thoratec, a global leader in ventricular assistance devices, where he served as Sales & Marketing Director from 2002 to 2011 and Sales Director EMEA from 2011 to 2013. He then joined CircuLite, a company developing a circulatory support system to treat chronic heart failure, as Sales Director for Southern Europe. Mr Richez holds a degree in Mathematics and training in Business & Management and Sales Force Management.

Francesco Arecchi

Mr. Francesco Arecchi has been Director of Marketing of Carmat SA since September 2017. A marketing professional with strong experience in global leading companies within the healthcare industry, Francesco Arecchi spent most of his career in Life Sciences companies such as Johnson & Johnson and Abbott, where he holds a number of positions from sales to marketing in Cardiology breakthrough technology products such as Cypher and MitraClip. Prior to joining Carmat, he stood as Product Manager EMEA Structural Heart at Abbott. Francesco Arecchi is a biomedical engineer and graduated from Politecnico di Milano (Italy) with an MBA from Rotterdam School of Management (Netherlands).

Raouia Bouyanzer

Ms. Raouia Bouyanzer is Director of Human Resources at Carmat SA. She has nearly 16 years of human resources and payroll experience. Her broad experience includes benefits, employee relations, payroll, talent acquisition and training. She started her career in 1998 in an accounting firm. In 2001, Raouia joined Morgan Stanley, where she held positions in social benefits management audit, payroll and human resources for more than 9 years. Raouia joined Carmat at the stage of the 'development' of the company in February 2011 as an Administrative and Financial Manager, and set up in 2012 the human resources policy. She is a graduate of ESSEC business school in Human Resources Management and holds a Financial and Accounting degree (2001).

Thierry Dupoux

Mr. Thierry Dupoux has been Senior Director of Quality Assurance at Carmat SA since July 30, 2018. He has worked most of his career for Life Sciences companies such as General Electric where he became Supply Chain Quality & Compliance Manager for the plant of Buc (France) in his last position. In 2006, he joined Sorin Group, now named LivaNova, a world leader in Cardiac Surgery and Neuromodulation. Over the past 12 years at LivaNova, he held several senior positions in Quality Assurance, Regulatory Affairs and R&D. Prior to joining CARMAT, he was Vice President of Quality Assurance at LivaNova where he led the integration of the Quality Systems following the merger between Sorin Group and Cyberonics.

Wenzel Hurtak

Mr. Wenzel Hurtak is Director of Manufacturing at Carmat SA. He is a seasoned medical device professional with a strong and broad expertise in R&D and manufacturing. engineering Graduate in Physics and Materials Science from the University of Groningen (The Netherlands), he has spent most of his career in Life Sciences companies such as Cordis / Johnson & Johnson where he held several management positions in manufacturing and process engineering as well as Advanced R&D. In 2004, he joined Integra LifeSciences Corporation, a world leader in Neurosurgery and Orthopaedics, where he became Vice President of European Operations. In that role, he was responsible for 5 manufacturing facilities across Europe and contributed to the development of over 10 products. Prior to joining Carmat, he was Business Director for new products at Contract Medical International GmbH, a leader in product development for minimally invasive devices in cardiology and various other applications.

Petrus Jansen

Dr. Petrus (Piet) Jansen has been the Medical Director of Carmat SA since December 2009. Dr. Jansen has held manager positions at medical device companies focused on Circulatory Support since 1997. He was Chief Medical Officer at World Heart Corporation in Oakland CA, USA from 2004 to 2009. Dr. Jansen was Vice President, Clinical Programs at Orqis International GmbH from 2003 to 2004; Vice President, Clinical Affairs at Jarvik Heart Inc. (New York, USA) from 2001 to 2003. From 1997 to 2001, Dr. Jansen worked for the Novacor Division of Edwards Lifesciences LLC, formerly Baxter Corporation. Prior to joining the medical device industry, he worked multiple years in cardiac surgery clinics in Amsterdam, the Netherlands. Dr. Jansen has a Doctorate of Medicine Degree from Radboud University Nijmegen, a PhD in Pathophysiology of Extracorporeal Circulation from the Free University Amsterdam and a Post-doctorate degree in Clinical Epidemiology from the Universiteit van Amsterdam.

Alain Carpentier

Prof. Alain Carpentier is Director of Carmat SA. He was firstly appointed as a Independent Director of the Company on May 7, 2010. He is Emeritus Professor at the Paris-Descartes University. He is also a Professor at the Mount Sinai School of Medicine in New York. As a member of the French Academy of Science and a winner of the 1998 Foundation for Medical Research Prize, he also received the Albert Lasker Award for Clinical Medical Research in 2007 in recognition of his two main contributions to the field: invention of the first valve bioprostheses (Carpentier-Edwards valves) and the development of techniques for plastic and reconstructive surgery of heart valves. Prof. Carpentier also serves as a Director of Fondation Singer Polignac and Association Recherche Scientifique de la Fondation Alain Carpentie.

Anne-Pascale Guedon

Ms. Anne-Pascale Guedon has been Director representing Matra Defense since March 20, 2015. She has has more than 25 years' experience in investment and M & A. She held a number of executive positions at leading companies such as Bouygues, Loxam and Credit Agricole and international firms including GE Capital and Man Group before joining Airbus. Since 2008, she has been Vice President Financial Engineering at Airbus Group, where she is responsible for managing funds to invest worldwide through joint ventures and acquisitions. Ms Guedon graduated from HEC business school and the French Society of Financial Analysts (SFAF). She is also an auditor of the 64th National Session of the National Institute for Defense Studies (IHEDN) and is a colonel in the French Air Force reserves.

Antonino Ligresti

Dr. Antonino Ligresti has been Director representing Sante Holdings SRL at Carmat SA since April 12, 2016. He began his career in the Medical Clinic at Milan University and at the city’s Fatebenefratelli Hospital. In 1979, following the gradual acquisition of several high-profile establishments in Lombardy, he created Italy’s first private hospital group, acknowledged for the quality of its services and patient-centric care, as well as its ties with teaching and academic research. Dr Ligresti joined the Générale de Santé board of directors in 2003 and became its chairman a year later. He was also instrumental in creating the European Oncology Institute. Dr Ligresti is a qualified physician and surgeon, specialising in cardiology and internal medicine.

Philippe Pouletty

Dr. Philippe Pouletty has been the Representative of Truffle Capital on the Board of Directors of Carmat SA since May 7, 2010. He also serves as Chairman of the Company's Compensation Committee. He qualified as a Medical Doctor and Immunologist from the Universite Paris VI and then gained clinical & research experience at the Pasteur Institute, the University of Stanford and the Paris Public Hospitals group. He is cited as an inventor on 29 patents. He has been made a Knight of the French Legion of Honour and was awarded the American Liver Foundation Prize in 1999. Dr. Pouletty is a founder and General Partner of the Truffle Capital private equity firm and also has founded several biotech companies in the USA and Europe (SangStat, Conjuchem, DrugAbuse Sciences). Dr. Pouletty serves currently as Chairman of Abivax SA, Manager of Nakostech SARL.

Pierre Bastid

Mr. Pierre Bastid has been Independent Director of Carmat SA since April 5, 2018. He currently serves as Chairman of Babalia and Director at Hougou, Cellectis and Pharnext. Former manager at Schneider Electric then Valeo, Pierre Bastid becomes in 1998 Vice President of Thomson Television Components France (Thomson Multimedia Group). In 2004, via the Magenta Participations structure, it successfully participated in the acquisition of Alstom Power Conversion, a group that later became Converteam Group, sold to General Electric in 2011. Since that date, Pierre Bastid manages his assets resulting from the sale of his shares of Converteam.

Henri Lachmann

Mr. Henri Lachmann has served as an Independent Director of Carmat SA since December 23, 2010. He started his career in 1963 at Arthur Andersen and in 1970 he joined Strafor Facom, whwre he became President in 1981. He was appointed Director of Schneider Electric in 1996 and became its Chairman and Chief Executive Officer in 1999. Mr. Lachmann holds several other positions, including Chairman of the Board of Directors at the CENTRE CHIRURGICAL MARIE LANNELONGUE, Chairman of the INSTITUT TELEMAQUE and Director of the FONDATION ENTREPRENDRE, among others. He graduated from Hautes Etudes Commerciales and is a Certified Chartered Accountant.

Jean-Luc Lemercier

Mr. Jean-Luc Lemercier has been Independent Director of Carmat SA since January 2, 2017. He is Member of company's Nominarting and Compensation Committee. He draws on more than 30 years’ experience and acknowledged leadership in medical devices. During his career, he has held a number of key positions in the field of cardiology, notably at Johnson & Johnson Cordis from 1996 to 2008, where he created and headed the Structural Heart Disease division. Since 2017, he has been Corporate Vice President EMEA, Canada & Latin America at Edwards Lifescience. Mr Lemercier graduated in pharmacy from Claude Bernard Lyon 1 University.

Michael Mack

Dr. Michael Mack has been Independent Director of Carmat SA since January 2, 2017. He is an internationally renowned cardiac surgeon with extensive experience in the introduction of medical devices and innovative procedures for cardiovascular disease. He has authored more than 650 scientific publications and has received the Presidential Citation from the American College of Cardiology (ACC) and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award. Dr Mack is a graduate of Boston College, St Louis University and the University of Texas Southwestern Medical School. He is also the Director of the Cardiovascular department for pharmaceutical firm Baylor Scott & White Health, a Director on the American Board of Thoracic Surgery and a member of the FDA Medical Device Epidemiology Network Initiative (MDEpiNet) Advisory Committee.